

Charlie Kim

Partner



ckim@cooley.com

+1 858 550 6049

San Diego

Capital Markets

Emerging Companies

Debt Finance

Life Sciences and Healthcare

Technology

Ecommerce + Marketplace

Food and Beverage

Retail and Consumer Products

Charlie is co-chair of Cooley's global capital markets practice group. He is a nationwide leader in capital markets transactions and has worked on 200+ successfully completed public company securities offerings since 2019 – including Uber's \$8.1 billion initial public offering (IPO) and three of the five biggest biotechnology IPOs to date. Charlie focuses on representing US and non-US issuers, investment banking firms and venture capital firms in public offerings and private placements of equity and debt securities. He also is co-chair of the Asian Pacific Islander Attorney Affinity Group at Cooley.

Charlie has worked on securities offerings by top innovative companies across industries, including: AbCellera, Accelerate, ACELYRIN, Acutus, Advaxis, Aerohive, Agenesis, Akari, Akcea, Akero, Allogene, Alteryx, Ambrx, Amylin, Anadys, AnaptysBio, Angion, Annexon, Anthera, Apogee, Applied Molecular Transport, Arcadia, Arcus, Arcutis, Ardea, Arena, Aridis, Artiva, Ascendis, ASLAN, Athira, Audentes, Avidity, Ballast Point Brewing & Spirits, Beta Bionics, BioAge, Biomea, Boundless Bio, Cadence, CARGO, Caris, CASI, Castlight, Cerus, CG Oncology, Cidara, Clorox, Corcept, Crinetics, Cue Health, Cyan, Cytos, Day One, Dermira, Design, DICE, Doximity, Dynavax, eBay, EHang, Eidos, Elevation Oncology, Entropic, Erasca, Exagen, Evofem, Fangdd, FIGS, FireEye, Five Prime, Gemphire, Genomatica, Global Blood, Gossamer, Gracell, Graphite Bio, Gritstone, Guardant Health, Halozyme, Health Catalyst, Healthcare Royalty, HealthEquity, Heartflow, Horizon, IGM, Ignyta, Immune Design, IMV, Inhibrx, Inovio, Invitae, Ionis, Janux, Jazz Pharmaceuticals, Kamada, Kinate, Kite Pharma, Kronos, Landry's, LifeLock, Limelight, Livongo, Longboard, Lyell, MannKind, Medallia, MethylGene, Metropark, MindBody, Minerva, Mirati, Mirion Technologies, NantHealth, NantKwest, Nektar, Neon, Neumora, Neurocrine, ObsEva, Olink, Ooma, Optimer, ORIC, Otonomy, Pernix, Phathom, Poseida, PRA Holdings, PROCEPT, ProfoundBio, Progressive Gaming, ProNAi, ProQR, Proto Labs, Qualtrics, Quidel, Radiant Systems, Rani, Raptor, RayzeBio, Reata, Receptos, Regulix, ReSearch Pharmaceutical Services, Sana, Sangamo, Santarus, Savara, Seattle Genetics, Senomyx, Septerna, Sequenom, ShockWave, Sierra, Silverback, Singular Genomics, Shoulder Innovations, Somaxon, Strongbridge, Structure, Surface Oncology, Sutro, Syndax, Tableau Software, Tabula Rasa, Taiwan Liposome Company, Tangoe, Tarsus, Third Harmonic, TRACON, Treace, Tricida, Trius, TriVascular, Uber Technologies, Upstream, Vaxcyte, Ventyx Biosciences, Verenium, Verona, Vical, ViewRay, Viking, Vir, Vital Therapies, Vor, Xencor, Xenon, XenoPort, Zealand Pharma, Zentalis, Zogenix, Zscaler, Zymeworks, 4D Molecular Therapeutics, 10x Genomics and 89bio.

Charlie regularly represents all the leading investment banks, including BofA Securities, Citigroup, Credit Suisse, Goldman Sachs, Jefferies, J.P. Morgan, Leerink, Morgan Stanley, Piper Sandler and TD Cowen.

Charlie also represented Jeff Moorad/JSM Acquisition in connection with their acquisition of the San Diego Padres MLB franchise.

Charlie is a regular panelist at numerous IPO preparation conferences every year. He has been a featured panelist for the Practising Law Institute's national "How to Prepare an Initial Public Offering" seminar, the Securities Regulation Institute's national panel on "Key issues in Capital Formation," the Asia and US Life Sciences Roadshow, and the BFC Global Healthcare Investment Conference focused on Asian healthcare companies and investors. He also has been a multiyear member of Law360's Capital Markets Editorial Advisory Board, and he served as a regular guest lecturer at the Entrepreneurship Clinic and in a course entitled "High Tech Start-Ups" at the University of San Diego School of Law. In addition, Charlie contributed to the widely read textbook, "The Entrepreneur's Guide to Business Law," as well as to Cooley's IPO handbooks.

Education

New York University School of Law JD, 2000

Princeton Theological Seminary MDiv, 1997

University of Michigan, Ann Arbor BA, 1994

Admissions & Credentials

California

New York

Court Admissions

US District Court for the Southern District of California

Rankings & Accolades

IFLR100 – Notable Practitioner (2025)

Forbes: America's Top Lawyers (2025)

Best Lawyers in America: Securities/Capital Markets Law (2026)

Chambers USA: Band 1: Capital Markets: Debt & Equity – California (2017 – 2025)

Chambers USA: Band 1: Capital Markets: Debt & Equity: Western United States – Nationwide (2019 – 2025)

The Legal 500 US: Leading Lawyer in Capital Markets: Equity Offerings (2024 – 2025)

Daily Journal: Top 100 Lawyer across all specialties in California and recipient of the California Lawyer Attorneys of the Year Award

The Daily Transcript: San Diego Top Attorney

Law360: MVP of the Year – Capital Markets

Thomson Reuters: Super Lawyer – Southern California and San Diego

Memberships & Affiliations

American Bar Association (ABA)

Council of Korean Americans

New York State Bar Association

San Diego County Bar Association